Product
Gemcitabine + Carboplatin
Aliases
Background Gemcitabine-based Chemotherapy Regimen, Gemcitabine + carboplatin, Gemcitabine plus Carboplatin, Platinum based Standard of Care Chemotherapy
8 clinical trials
9 indications
Indication
CancerIndication
Non Small Cell Lung CancerIndication
Bile Duct CancerIndication
Non Small Cell Lung CarcinomaIndication
Non-Small-Cell Lung CarcinomaIndication
Ovarian CancerIndication
Fallopian Tube NeoplasmsIndication
Primary Peritoneal NeoplasmIndication
Triple-Negative Breast CancerClinical trial
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-07-05
Clinical trial
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)Status: Active (not recruiting), Estimated PCD: 2021-03-12
Clinical trial
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE)Status: Recruiting, Estimated PCD: 2025-09-17
Clinical trial
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).Status: Active (not recruiting), Estimated PCD: 2020-09-21
Clinical trial
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).Status: Active (not recruiting), Estimated PCD: 2018-10-04
Clinical trial
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian CancerStatus: Terminated, Estimated PCD: 2012-11-01
Clinical trial
A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2022-10-27